Cascade Carrier‐Free Nanoparticles Forming In Situ Nanovaccines for Synergistic Photothermal‐Immunotherapy of Cancer

Rapid advances in nanotechnology have made it possible to combine photothermal therapy (PTT) with immunotherapy, enabling to activate an in situ vaccine effect. However, this effect is severely impeded by low antigen presentation level and highly suppressive tumor immune microenvironment (immune “co...

Full description

Saved in:
Bibliographic Details
Published in:Advanced functional materials 2024-07, Vol.34 (29), p.n/a
Main Authors: Huang, Chenlu, Wang, Hanyong, Yang, Xinyu, Yu, Qingyu, Wang, Hai, Zhang, Linhua, Zhao, Yanli, Zhu, Dunwan
Format: Article
Language:English
Subjects:
Antigens
carrier‐free nanoparticles
Current carriers
immunosuppressive microenvironment reversal
immunotherapy
in situ nanovaccines
Lipids
Nanoparticles
photothermal therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rapid advances in nanotechnology have made it possible to combine photothermal therapy (PTT) with immunotherapy, enabling to activate an in situ vaccine effect. However, this effect is severely impeded by low antigen presentation level and highly suppressive tumor immune microenvironment (immune “cold” tumors). To overcome the obstacles, multifunctional carrier‐free nanoparticles (FCDP‐NPs) assembled from Fe2+, toll‐like receptor 9 agonist (CpG), cationic lipid (DOTAP) and photothermal agent polydopamine are developed. After intratumoral injection, FCDP‐NPs carrying positive charge are exposed under laser irradiation, which can capture tumor‐associated antigens (TAAs) generated upon post‐PTT to form the nanovaccines (FCD‐NPs@TAAs). The nanovaccines further promote cross‐presentation of TAAs, stimulate adaptive immune responses, and shape immune “hot” tumors. As a result, in situ nanovaccines highly improve survival rates and elicit a durable immune memory that remarkedly prevents tumor metastasis, illustrating a useful platform for PTT synergized with immunotherapy. By taking advantage of the convenient approach with one‐pot method and graded assembly method, a multifunctional carrier‐free nanoparticle is developed to form an in situ vaccine for photothermal synergistic immunotherapy of tumor. This cascade therapeutic paradigm reverses immunosuppressive tumor microenvironment, potentiates primary tumor eradication, and procures enduring immune memory to inhibit tumor metastasis.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.202401489